Clovis Oncology Inc. (NASDAQ:CLVS) shares were up 5.1% during mid-day trading on Thursday after Stifel Nicolaus raised their price target on the stock from $30.00 to $45.00. Stifel Nicolaus currently has a buy rating on the stock. Clovis Oncology traded as high as $37.97 and last traded at $37.51, with a volume of 3,535,686 shares trading hands. The stock had previously closed at $35.68.
A number of other research analysts have also issued reports on CLVS. Vetr lowered shares of Clovis Oncology from a “strong-buy” rating to a “buy” rating and set a $17.66 target price on the stock. in a report on Wednesday, May 25th. Credit Suisse Group AG reaffirmed a “hold” rating on shares of Clovis Oncology in a research note on Wednesday, June 8th. Piper Jaffray Cos. reaffirmed a “hold” rating and set a $14.00 price objective on shares of Clovis Oncology in a research note on Wednesday, June 29th. SunTrust Banks Inc. initiated coverage on shares of Clovis Oncology in a research note on Friday, August 5th. They set a “buy” rating and a $25.00 price objective for the company. Finally, JPMorgan Chase & Co. reaffirmed a “hold” rating and set a $13.00 price objective on shares of Clovis Oncology in a research note on Tuesday, August 9th. Six analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $32.20.
A number of institutional investors have recently added to or reduced their stakes in CLVS. Fox Run Management L.L.C. bought a new position in Clovis Oncology during the second quarter worth $154,000. Kazazian Asset Management LLC bought a new position in Clovis Oncology during the first quarter worth $282,000. Bellevue Group AG bought a new position in Clovis Oncology during the first quarter worth $1,008,000. Schonfeld Strategic Advisors LLC bought a new position in Clovis Oncology during the first quarter worth $233,000. Finally, Boston Partners bought a new position in Clovis Oncology during the second quarter worth $1,540,000. Hedge funds and other institutional investors own 98.46% of the company’s stock.
The company’s market capitalization is $1.46 billion. The firm has a 50-day moving average price of $22.84 and a 200-day moving average price of $17.30.
Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($2.07) EPS for the quarter, topping the Zacks’ consensus estimate of ($2.13) by $0.06. During the same period last year, the business earned ($2.10) EPS. On average, equities analysts forecast that Clovis Oncology Inc. will post ($9.32) earnings per share for the current year.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.